Viomi Technology Co., Ltd - American Depositary Shares (VIOT)
Live price chart, market sentiment, and community perspectives for Viomi Technology Co., Ltd - American Depositary Shares (NASDAQ: VIOT).
Live price chart, market sentiment, and community perspectives for Viomi Technology Co., Ltd - American Depositary Shares (NASDAQ: VIOT).
On our desk, the macro picture for Chinese household durables looks deeply concerning. Government data from May showed large consumer purchases like home appliances dropped 20%, and the absence of a renewed subsidy program has completely undermined Viomi's top-line revenue. Total revenue for the second half of 2025 dropped 25.9% to RMB 950.6 million primarily due to lower home water system sales and price declines. Even though quantitative valuation engines like CirclFi rate the company's fundamental quality at 8.4 out of 10, the market sentiment in the US remains heavily skewed toward a 'Sell' rating due to the complete evaporation of the subsidy tailwind.
Watching the technical indicators and exchange compliance requirements, VIOT is walking a very thin line. The company officially received a Nasdaq minimum bid price deficiency notice on July 23, 2026, after closing below $1.00 for 30 consecutive business days. They now have a ticking clock until January 19, 2027, to stay listed. Trading down with a market cap hovering around $51M to $73M and low institutional ownership near 1.22%, the stock has experienced heavy selling pressure and significant underperformance compared to its domestic peers. Investors are forced to weigh a low valuation against the very real structural risk of a sub-dollar share price.
From a fundamental modeling perspective, analysts are fiercely divided on how to price Viomi's recovery window for late 2026 and 2027. Zacks Research is projecting a hopeful turnaround with FY2027 earnings reaching $0.17 per share, a massive shift from current consensus full-year losses of ($0.11) per share. However, operational headwinds remain severe: home water system revenue fell 32.1% and consumables dropped 17.9% in their latest results. When building out discounted cash flow models for this name, analysts must discount heavily for channel adjustments, ongoing price sensitivity in the Chinese domestic market, and the absolute lack of formal guidance for 2026.
Explore plasma cleansing, somatic organ swaps, and BCI.